TransMedics Group (TMDX) Announces Proposed $60M Public Offering of Common Stock

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $60 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15 percent of the number of shares sold in the offering.

J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. Canaccord Genuity is acting as lead manager for the proposed offering.

A shelf registration statement on Form S-3 relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (the “SEC”) on May 21, 2020. Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that TransMedics will file with the SEC for more complete information about TransMedics and this offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the SEC website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, by visiting the SEC website at www.sec.gov or from J.P. Morgan Securities LLC, c/o J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone, at (866) 803-9204 or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

You May Also Be Interested In

• Manulife prices $750M subordinated notes offering at 6.146%
• California Resources completes $63M acquisition of Crimson Midstream
• Intelligent Bio Solutions raises $5M in private placement